shoumik (@shmkdbr) header
shoumik (@shmkdbr) profile picture

investing https://nitter.cf/t.co/OmxXzAeGyh , learning @legiblebio

Joined June 2012
Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)Photo by shoumik (@shmkdbr)
Normie hedgies unable to cope with everythingiscrypto meta
BILL ACKMAN: STOCK MARKET IS "BROKEN" BY SPECULATIVE TRADING Pershing Square founder Bill Ackman warns that excessive leverage and speculation are driving irrational stock-price swings. Ackman compared today's trading environment to casino-style markets, criticizing leveraged products and perpetual futures. However, he said the volatility has created buying opportunities for Pershing Square, including Microsoft, Amazon and Alphabet. He also praised Visa and Mastercard as two of the world's greatest businesses and highlighted Netflix as a portfolio holding.
3
135
peter thiel is the only one who understands that the whole point of getting rich is getting people to take your essays seriously
71
659
59
10,620
264,833
shoumik retweeted
Miniature one sided MRI we built at Aion, early prototype In the future you won't have to be in a claustrophobic MRI tube to be scanned. Our goal is to make this a comfortable bed you can sleep on every night
22
24
3
376
19,100
can’t believe druck did this to binance
3
168
shoumik retweeted
Ratatouille is such a great movie because it’s ruthlessly in favor of meritocratic inegalitarianism. “Anyone can cook,” not “everyone can cook.” The duty of Chef Linguini is to forfeit his arbitrary inherited status as a human and serve to elevate the deserving übermaus Remy.
47
435
39
8,724
180,204
The reason you see so many crypto folks more active in biotech now (me) is bc of how similar the two markets actually are Immense volatility, global ambitions, high failure rate, heavy handed regulatory burdens, etc etc.
Bit sad to see how biotech has become such a marketing game. Before, it was mostly nerdy scientists who wanted to help patients. Now everything has become so hyperbolic. I get that it's a necessary evil if you want to do well with fundraising, but I think some forget what's important.
3
13
1,042
shoumik retweeted
I agree. Robots are the non-biologist's abstraction of how scaling in biology scales. Imagine people in the 1940s pouring money 100x money into automating the vacuum tube factory than inventing the transistor. Imagine putting everything into giant CPU factories instead of inventing the GPU. We are disproportionally thinking/resourcing innovation in biology as if it's car manufacturing. There is ample opportunity to improve, redefine and scale measurement in front of us. I recently talked to someone at a robot-first science factory with near billion in funding boasting how they measure ~1000 mutants a week. A team of 4 at Dyno scaled the equivalent assay multiplexing by 25x. 1 person can run it. The robot is scaling the wrong layer. I'm not against robots and I think they will have the role to play. But I think their impact on biology is overblown, especially on how it scales in performance per dollar deployed. The danger is we become so obsessed with vacuum tube factories that we don't fund the transistors of biology. Complex physical value chains are somewhat path dependent, once you build a highway instead of a subway, you have to deal with a lower efficiency, higher pollution world. Most current robotic approaches are a crude, and poorly scalable, way to scale biology.
Maybe controversial: the conversation about scientific bottlenecks is overfocused on automation. New measurement technologies deserve more attention. You could automate an assay that needs an entire facility – or you could REINVENT the assay so that it fits into just a few tubes.
28
54
13
352
30,654
shoumik retweeted
“shift focus [to] moneymaking endeavors … [such as] biotech” 😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂
Random predictions, loosely held Anthropic IPO marks the high water mark of this cycle, the cherry on top. A natural and convenient point to exit all public equities for funds up many multiples in the last few years OpenAI has to go out as well, private markets tapped out for their needs, but reduces valuation as public markets reprice Anthropic. Generally think they trade very similarly to each other once public. The commodity saxophones get louder. If they do end up becoming the utilities of intelligence, does it mean they have limited price appreciation and end up paying a dividend?? IPO window slams shut for all but a select few. Databricks goes public but Stripe continues to delay. They never go public and pioneer a new kind of private company structure because they like to do out of the box things The quarterly reporting cadence of public markets prove unfriendly to the frontier labs and they wish they could've stayed private. Wall Street struggles to digest their business model and rate of spending. Constant model releases fall out deaf ears as people tune out marginal improvements until people are caught off guard by AGI. Market as a whole cools for at least 18 months as everyone waits for "the next breakthrough" Labs further shift focus from frontier intelligence to moneymaking endeavors - vertical and industry focused initiatives in biotech, applied AI deployments, F500 contracts Everything public in the AI ecosystem trades downstream of the labs and acts as levered beta, any weakness in lab numbers is punished severely across the board. Private companies remain insulated from this to a certain extent but the exuberance we see there is significantly dampened as investors now have a public benchmark to work backwards from. NVIDIA buys up all the neolabs for acquihires and backstops the neoclouds but declining stock price due to macro conditions curtails their enthusiasm after a while, they can only cover so much. If they haven't invested in you, you don't spend heavily on GPUs or don't have a personal connection, you're on the outside looking in Surviving SaaS dinosaurs that have good economics are able to get their M&A machines going again to pick up the scraps. Many cutting edge AI startups turn out to have been public R&D projects Using AI to solve real world problems becomes "higher status" than working at a frontier lab for most roles. People become fixated with the idea of real world impact Robotics IPOs are for next cycle, this time around the exits will mainly come via M&A to existing industrial giants who need to catch up
2
3
1
171
8,242
shoumik retweeted
Crypto’s role in monetizing obscure power resources in far-flung corners of the globe is underappreciated in the AI buildout Siberian and Bhutanese bitcoin walked so Paraguayan and Kazakh compute could run
1
1
1
24
3,210
shoumik retweeted
one of the most ambitious humans alive: @isaakfreeman — if you are a chemist or biologist you should join their team while it’s still a startup help make humans more capable while building out some of the most advance automated labs out there!
2
3
53
2,959
I’m as AI safety-pilled as the next guy, but if you’re the OpenAI employee responsible for teaching the models to speak normie patois, you’ve done more damage than every “misaligned” action combined
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
36
73
11
2,727
77,419
shoumik retweeted
Would you choose your healthiest embryo? @herasight ranks embryos by predicted disease risk, height, autism risk, and even IQ. I sat down with @JonathanAnomaly to separate the real science from hype and dig into the ethics of creating future people. Full episode:
Embryo selection and the science of creating future people with @JonathanAnomaly from @herasight 00:00 - From Academia to Herasight 07:12 - Is Embryo Selection Controversial 11:31 - Polygenic Scores Explained 21:14 - Why Insurance Hasn’t Covered It 28:18 - Who Uses Screening and Why 32:35 - IVF Limits and Future Tech 36:52 - Selection vs Editing and Gattaca Fears 42:07 - Ethical Boundaries 43:01 - Breakthrough Imputation Proof 48:49 - Winning Clinics Over 51:18 - Ethics Backlash Explained 55:28 - Preference Cascade Theory 59:19 - Blank Slate Debate 01:03:09 - Pleiotropy Tradeoffs 01:08:29 - Autism Risk Predictor 01:13:37 - Repro Tech And Birth Rates 01:20:17 - Relationships And Family Futures 01:24:25 -Books Recs
1
5
471
shoumik retweeted
I’m from San Francisco, grew up in Texas, and my family is from India. I find people who get worked up about any of these types of questions to usually be way oversensitive. Almost always it’s just someone making conversation.
Treating “Where are you from?” as some sort of racial slight has always been a sign of insecurity/shame. If you’re proud of your identity, you should be eager to yap about it at length. But if you’re secretly embarrassed of it, then such a question would make you huff.
29
10
2
291
15,365
Every cell on our planet has come from other cells. A single blade of grass is more advanced technology than rockets, medicine and quantum computers. We cannot even come close to creating cells from scratch. And then lets talk about brains, we don't even know how memories are stored or why we sleep! I think it's pretty safe to assume that consciousness is much more complicated than a model you can run on a few couple year old gpus.
Mostly an intuition that biological life has innate value that cannot be artificially replicated. But I’m far from certain, and what creeps me out are the people on here who *already* seem eager to permanently cede the rights of known living things (humans, animals, biosphere) in a misguided worship of something that is only a mimicry of life. “Beware false idols” persisted in the bible for good reason!
15
9
2
104
7,630
Embryo selection is one of the most interesting technologies out there. If you could choose your kid’s height, would you? What about intelligence? Or more saliently, the risk of key diseases that your kid might be predisposed to? And how do we even know the tech is real? I discuss all this and more with @JonathanAnomaly , whose company @herasight is imputing polygenic risk scores for embryos based on fairly accessible inputs. The quagmire of ethical and scientific questions all this presents, I think, is ultimately tractable and offers reason for optimism
Embryo selection and the science of creating future people with @JonathanAnomaly from @herasight 00:00 - From Academia to Herasight 07:12 - Is Embryo Selection Controversial 11:31 - Polygenic Scores Explained 21:14 - Why Insurance Hasn’t Covered It 28:18 - Who Uses Screening and Why 32:35 - IVF Limits and Future Tech 36:52 - Selection vs Editing and Gattaca Fears 42:07 - Ethical Boundaries 43:01 - Breakthrough Imputation Proof 48:49 - Winning Clinics Over 51:18 - Ethics Backlash Explained 55:28 - Preference Cascade Theory 59:19 - Blank Slate Debate 01:03:09 - Pleiotropy Tradeoffs 01:08:29 - Autism Risk Predictor 01:13:37 - Repro Tech And Birth Rates 01:20:17 - Relationships And Family Futures 01:24:25 -Books Recs
1
3
1
20
1,185
the point of being a hater is having taste. For everything you hate on you must have something you just as enthusiastically recommend. Otherwise you’re a cancer upon society
97
5,072
230
34,516
515,531
shoumik retweeted
Tomorrow with @JonathanAnomaly from @herasight We discuss the tech behind embryo selection, how to reduce suffering, and the liberterian ethics underlying it all
2
2
8
382
The masses yearn for the most milquetoast innocuous takes
Better have a better long term business than selling data to labs
4
245
when purchasing data, pharma wants to know how the data will help advance a particular program or make a specific development decision. for the AI labs, the question is whether the dataset improves a model’s ability to understand and predict biology across many problems. that creates demand for data/experiments who’s value is distributed across many future programs. initially, the labs may buy whatever useful biological datasets exist (indiscriminate), but eventually demand will shift toward commissioning specific experiments that resolve gaps in a model’s understanding (discriminate).
6-12 months ago the large labs started buying bio data this spend is starting to ramp very aggressively. the labs are somewhat indiscriminate buyers with enormous budgets. the therapeutics market has long had buyers of data (large and small pharma) but they've historically been the exact opposite of huge-budget and indiscriminate this shift will distort the bio startup market in a bunch of ways. there will be a lot of short-termist behavior to try to get in front of this capital firehouse. but unlike the AI data labelers (mercor, et al) and the robotics labelers (mecka, et al), the bio startups serving up this data have a chance to emerge from this period with businesses that don't rely on selling data the best bio startups will use these sudden resources the labs are dumping on them to supercharge their novel assay and work towards independently powerful models and eventually directly produce therapies bio is the final frontier and its a very exciting time ahead for bio startups IMO
6
11
4
131
13,080